The diagnosis of Alzheimer’s disease(AD)relies on the clinical evaluation of patients,often complemented by the analysis of core cerebrospinal fluid(CSF)biomark-ers(Aβ42/40,phosphorylated-Tau and total-tau)[1].Howev...The diagnosis of Alzheimer’s disease(AD)relies on the clinical evaluation of patients,often complemented by the analysis of core cerebrospinal fluid(CSF)biomark-ers(Aβ42/40,phosphorylated-Tau and total-tau)[1].However,it is clear nowadays that alterations other than Aβand tau deposition,e.g.,blood-brain-barrier(BBB)impairment[2]and impaired protein clearance[3],may take place in early disease stages,before consistent neu-rodegeneration occurs.Therefore,additional CSF bio-markers are needed.展开更多
基金MO,LP,PN SM and NGSJ are supported by the Marie Skłodowska-Curie grant agreement No.860197—MIRIADE project(European Union’s Horizon 2020 research and innovation program)GB is supported by the Postdoctoral Fellowship for Basic Scientists grant of the Parkinson’s Foundation(Award ID:PF-PRF-934916)+2 种基金LP and LG are funded by the European Union—Next Generation EU—PNRR M6C2—Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN(PNRR-MAD-2022–12376035)LB is supported by the Medical Faculty of Martin-Luther University Halle Wittenberg(Junior Clinician Scientist Programm No.JCS24/02)SAB received research support from the Medical Faculty of Martin-Luther University Halle-Wittenberg(Clinician Scientist-Programm No.CS22/06).
文摘The diagnosis of Alzheimer’s disease(AD)relies on the clinical evaluation of patients,often complemented by the analysis of core cerebrospinal fluid(CSF)biomark-ers(Aβ42/40,phosphorylated-Tau and total-tau)[1].However,it is clear nowadays that alterations other than Aβand tau deposition,e.g.,blood-brain-barrier(BBB)impairment[2]and impaired protein clearance[3],may take place in early disease stages,before consistent neu-rodegeneration occurs.Therefore,additional CSF bio-markers are needed.
